Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3021-3030 Newer>

The Motley Fool July 14, 2006 Stephen D. Simpson	The Diverging Fortunes of Forest and Teva If a patent ruling holds up, Forest's prospects are much stronger. Unfortunately, the easy money has long since been made in Forest and today's announcement will almost certainly mean another big jump in the stock price.
The Motley Fool July 14, 2006 Stephen D. Simpson	FDA Bloodies Nastech's Nose An FDA rejection for a generic drug is a setback, but not a major one. Experienced biotech investors realize that ideas like Nastech are often binary outcomes -- it's either going to be a big winner or a total flop.
HBS Working Knowledge July 12, 2006 Roger Thompson	Competition the Cure for Healthcare Michael Porter is considered by many the world's foremost authority on competition and strategy. So when he discusses the need for fundamental reform in the way the United States delivers healthcare, people listen.
The Motley Fool July 12, 2006 Brian Lawler	Genzyme Continues to Deliver The biopharmaceutical company releases their second quarter earnings announcement. The stock is up sharply today, almost 8%, after Genzyme reported earnings of $0.68 a share.
The Motley Fool July 12, 2006 Stephen D. Simpson	Genentech's Deceptive Disappointment A slight shortfall in one product's sales is not a valid cause for panic. However, investors' patience might be wearing a bit thin here. What's more, Genentech's neither cheap nor undiscovered.
BusinessWeek July 17, 2006 Catherine Arnst	The Best Medical Care In The U.S. How Veterans Affairs transformed itself - and what it means for the rest of us.
The Motley Fool July 10, 2006 Brian Lawler	Northfield Frowns on Focus From "20/20" The maker of artificial blood finds yet another critic. But the impending end of the PolyHeme trial probably won't represent the end of criticism of the artificial blood. Only if good clinical trial results are announced later this year will Northfield's critics be silenced.
The Motley Fool July 10, 2006 Brian Lawler	CV Therapeutics Gets Greenlighted A final trial could secure full FDA approval for angina drug Ranexa. Investors, take note.
InternetNews July 7, 2006 Erin Joyce	The RFID Growth Conundrum Why isn't the FDA pushing harder for RFID to combat counterfeit drugs? The answer is not so simple.
BusinessWeek July 17, 2006 Arlene Weintraub	From Pfizer, Irrational Exubera? Pfizer's insulin inhaler may not be as big a diabetes blockbuster as expected.
<Older 3021-3030 Newer> Return to current articles.